Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29207051 | 0.86 | NPC1 (0.81) | NPC1SMN1; SMN2RAB9APOLBBLM | |
| SCHEMBL8247682 | 0.82 | SMN1; SMN2 (0.63) | NPC1SMN1; SMN2RAB9APOLBBLM | |
| SCHEMBL6204433 | 0.82 | MAPT (0.54) | NPC1SMN1; SMN2RAB9ASLC2A1MEN1 | |
| SCHEMBL29207098 | 0.81 | MAPT (0.64) | NPC1SMN1; SMN2RAB9APOLBBLM | |
| SCHEMBL1144017 | 0.81 | MAPT (0.64) | NPC1SMN1; SMN2RAB9APOLBBLM | |
| SCHEMBL11643263 | 0.81 | PTPN7 (0.56) | NPC1RAB9APOLBSLC2A1MEN1 | |
| SCHEMBL6181838 | 0.81 | NPC1 (0.73) | NPC1SMN1; SMN2RAB9APOLBBLM | |
| SCHEMBL3991159 | 0.81 | RXFP1 (0.56) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL29207027 | 0.80 | NPC1 (0.76) | NPC1SMN1; SMN2RAB9APOLBBLM | |
| SCHEMBL15179040 | 0.80 | NPC1 (0.76) | NPC1SMN1; SMN2RAB9APOLBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896478-B1 | Aspartyl protease inhibitors | MERCK SHARP & DOHME (US) | 2014-05-21 | — | — | EP | disclosed |
| US-7868000-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868000-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-01-11 | — | — | US | disclosed |
| US-20070060575-A1 | Aspartyl protease inhibitors | MERCK SHARP & DOHME LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060575-A1 | Aspartyl protease inhibitors | MERCK SHARP & DOHME LLC | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060575-A1 | Aspartyl protease inhibitors | CHRM2, BACE1, CHRM1 | NPC1 1782/4885SMN1; SMN2 934/4885RAB9A 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.